<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862533</url>
  </required_header>
  <id_info>
    <org_study_id>BELA2020</org_study_id>
    <secondary_id>URIRAPRO(2020)</secondary_id>
    <nct_id>NCT04862533</nct_id>
  </id_info>
  <brief_title>Effect of Beta-alanine and Pelvic Floor Muscle Training on Urinary Incontinence After Radical Prostatectomy (BELA)</brief_title>
  <acronym>BELA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Beta-alanine and Pelvic Floor Muscle Training on Urinary Incontinence After Radical Prostatectomy (BELA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Olomouc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of beta-alanine in combination&#xD;
      with pelvic floor muscle training (PFMT) compared to PFMT plus placebo in men undergoing&#xD;
      radical prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess efficacy of beta-alanine in combination with PFMT for the treatment of&#xD;
      participants with urinary incontinence after radical prostatectomy. B-alanine is a component&#xD;
      of L-carnosine (with L-histidine), which is needed for its synthesis. Βeta-alanine, thanks to&#xD;
      its bioavailability) is a commonly used supplement that can improve exercise performance by&#xD;
      increasing the amount of carnosine in striated muscle tissues. Supplementation of&#xD;
      beta-alanine in elderly patients has resulted in an increase in physical activity, less&#xD;
      fatigue and overall increase in L-carnosine concentration in muscles. PFMT utilization is&#xD;
      considered a strong predictor of early return of urinary continence after radical&#xD;
      prostatectomy (RP). We hypothesize, that combination of PFMT with beta-alanine could result&#xD;
      in improved urinary continence after RP. The intervention will start 30 days before the&#xD;
      surgery and will continue until primary outcome is met. Beta-alanine/placebo will be given&#xD;
      daily. Efficacy, pharmacokinetics, biomarkers, tissue histology, participants reported&#xD;
      outcomes and safety will be assessed. The total duration of study will be approximately 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Continence (days)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Continence is defined by number of pads used and measured by one hour pad test. Number of pads use will be determined according to EPIC-SF questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of physical activity of participants</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To assess physical activity of the participants using Physical activity level (PAL), the number of participants having recommended PAL (PAL 1.75: a weekly average PAL of ≥1.75) &lt; 1.4 = extremely inactive, &gt; 2.4 = extremely active</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities as measure of safety</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants with laboratory abnormalities (hematology, serum chemistry and liver function test) will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of adverse events in the combined beta-alanine and PFMT compared to PFMT and placebo treatment. Surgical complications will be evaluated according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life (QoL) change in both groups of participants</measure>
    <time_frame>up to 6 months</time_frame>
    <description>During the study period, participants will be asked to fill in clinical validated EuroQuol-5dimensions-5levels (EQ-5D-5L) questionnaire 0 = the worst to 100 = the best QoL outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle carnosine concentration</measure>
    <time_frame>at week 4 (surgery)</time_frame>
    <description>Integrity and architecture of muscle tissue will be assessed in 4 µm thick sections of formalin-fixed, paraffin-embedded, hematoxylin-eosin stained tissue samples.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Beta-Alanine</condition>
  <condition>Pelvic Floor Muscle Training</condition>
  <condition>Radical Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Beta-alanine + PFMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + PFMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-Alanine</intervention_name>
    <description>Participants will receive 1150mg of beta-alanine three times a day</description>
    <arm_group_label>Beta-alanine + PFMT</arm_group_label>
    <other_name>Intervention group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo three times a day</description>
    <arm_group_label>Placebo + PFMT</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               -  Age 40-80 years&#xD;
&#xD;
               -  Able to give informed consent&#xD;
&#xD;
               -  Histologically proven prostate cancer&#xD;
&#xD;
               -  BMI &lt;35&#xD;
&#xD;
               -  No other cancer treatment&#xD;
&#xD;
               -  Continent&#xD;
&#xD;
               -  Good physical and mental activity&#xD;
&#xD;
               -  On normal diet&#xD;
&#xD;
               -  Scheduled for radical prostatectomy (open or robotic)&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               -  Other malignant cancer (except for benign skin cancer)&#xD;
&#xD;
               -  Age &gt; 80 years&#xD;
&#xD;
               -  Diabetes mellitus (any type)&#xD;
&#xD;
               -  Chronic bowel inflammatory disease&#xD;
&#xD;
               -  Urinary incontinence&#xD;
&#xD;
               -  Impaired mental activity&#xD;
&#xD;
               -  Previous radiotherapy of hormonal therapy&#xD;
&#xD;
               -  Vegetarian/vegan/on macrobiotic diet&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Student, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. of Urology, University hospital Olomouc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Student, MD, PhD</last_name>
    <phone>737807881</phone>
    <phone_ext>+420</phone_ext>
    <email>vladastudent@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Student, MD,PhD</last_name>
      <phone>737807881</phone>
      <phone_ext>+420</phone_ext>
      <email>vladastudent@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Student, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Olomouc</investigator_affiliation>
    <investigator_full_name>Vladimir Student, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Director of the study</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

